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Abstract
Purpose—Reflex human papillomavirus (HPV) testing is the preferred triage option for most 
women diagnosed with atypical squamous cells of undetermined significance (ASC-US). This 
study was conducted to describe follow-up results of women with ASC-US Pap test results in the 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP), focusing on HPV test 
use.
Methods—We examined the follow-up of 45,049 women in the NBCCEDP with ASC-US Pap 
tests during 2009–2011. Data on demographic characteristics, diagnostic procedures, and clinical 
outcomes were analyzed.
Results—NBCCEDP providers diagnosed 45,049 women (4.5 % of all Pap tests) with an ASC-
US result. Of those, 28,271 (62.8 %) were followed with an HPV test, 3,883 (8.6 %) with a repeat 
Pap test, 6,592 (14.6 %) with colposcopy, and 6,303 were lost to follow-up (14.0 %). Women aged 
40 and older were followed more often with an HPV test. White, black, and Asian/Pacific Islander 
women were followed more often with an HPV test after an ASC-US Pap compared to Hispanic 
and American Indian/Alaska Native (AI/AN) women. Among women with a positive HPV test on 
follow-up, almost 90 % continued with colposcopy as recommended. AI/AN women had the 
highest rates of HPV positivity (55.2 %) and of no follow-up (25.0 %).
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Conclusion—This is the first analysis describing follow-up of ASC-US Pap test results in the 
NBCCEDP, providing a window into current management of ASC-US results. Findings raise 
concerns about persistent disparities among AI/AN women. During 2009–2011, nearly two-thirds 
of women with an ASC-US Pap test result were followed with an HPV reflex test.
Keywords
HPV testing; ASC-US; NBCCEDP; Pap test
Introduction
Each year, more than two million women in the USA are diagnosed with a mild Pap test 
abnormality called “atypical squamous cells of undetermined significance” (ASC-US) [1]. 
ASC-US is a Pap test result classification that is ambiguous, by definition [2]. ASC-US 
findings are generally either indicative of reactive changes (due to irritation or minor 
infections) or precancerous lesions indicating human papillomavirus (HPV) infection, but 
can rarely raise concern that more significant lesions may be present [2, 3]. ASC-US lesions 
are also subjective and depend on a pathologist's interpretation [4]. HPV-positive test results 
subsequent to an ASC-US result indicate a possible pre-cancer and should be evaluated with 
colposcopy, while HPV-negative ASC-US findings help ensure that abnormalities are likely 
benign [1]. Thus, reflex HPV testing serves as an ancillary test used after an ASC-US result 
to determine whether more follow-up is needed (in the case of a positive HPV test). The 
2006 American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines stated 
that HPV testing was the preferred follow-up method after an ASC-US Pap test result and 
that repeat Pap testing and immediate colposcopy were also acceptable methods [5].
The Centers for Disease Control and Prevention's (CDC) National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP) is the only national organized cancer 
screening program for low-income, uninsured, and underinsured women [6]. The 
NBCCEDP recommends their programs follow ASCCP guidelines for management of 
abnormal Pap tests. The NBCCEDP began reimbursing providers for HPV tests as an option 
for ASC-US Pap follow-up after FDA approval in 2003 [7]; however, HPV test data were 
not systematically reported to CDC until NBCCEDP data collection was expanded in 2009. 
In this paper, we examined the follow-up of women being screened in the NBCCEDP with 
an ASC-US Pap result during 2009–2011 to determine how providers serving this 
population of underserved women are following up on ASC-US results.
Methods
CDC has established cooperative agreements with states, American Indian/Alaska Native 
tribes, and territories to provide screening, referral, and follow-up services to women 
through the NBCCEDP, described in detail elsewhere [6, 8]. Since the NBCCEDP's 
inception in 1991, CDC has collected a set of standardized data items to monitor screening, 
diagnostic follow-up, and treatment initiation activities [8]. Women reported demographic 
characteristics and prior screening history at enrollment. Providers reported dates and results 
of Pap tests as well as any diagnostic procedures, outcomes, and the date of treatment 
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initiation if applicable. This study used data reported during January 2009–December 2011 
from 50 states, the District of Columbia, 12 tribes, and five territories.
Study outcomes
We examined data on women screened by the NBCCEDP and diagnosed with an ASC-US 
Pap test result, as classified by the Bethesda System [1]. Data on follow-up of ASC-US Pap 
tests extended for 15 months from the time of screening. We selected the women's first 
ASC-US Pap during the study period and excluded women who had a previous ASC-US or 
other abnormal Pap through the NBCCEDP to remove from the study any women 
potentially under management for a previous abnormality.
We calculated age based on the birth date at time of ASC-US Pap diagnosis using six age 
classifications: 18–20, 21–29, 30–39, 40–49, 50–64, and 65 years or older. The age groups 
were selected after consideration of age-related influences on screening rates, primarily 
guidelines recommending screening initiation at age 21 [9] and Medicare benefits for those 
aged 65 years and older. Women reporting Hispanic ethnicity were classified as Hispanic 
regardless of race. Other women were classified as white; black; Asian, native Hawaiian, or 
other Pacific Islander (API); American Indian/Alaska Native (AI/AN); or multiracial.
During 2009–2011, the NBCCEDP performed Pap tests on 993,238 women, of which 
45,049 (4.5 %) had an ASC-US result. This study examined the follow-up of these 45,049 
women with ASC-US Pap tests, including clinical outcomes for HPV reflex tests for triage, 
repeat Pap tests (using the Bethesda System for reporting), and biopsy-directed colposcopies 
to report cervical intraepithelial neoplasia (CIN) and invasive cancers. Women were 
categorized into three mutually exclusive groups by follow-up procedure: repeat Pap test 
(with no HPV test or colposcopy associated with the initial ASC-US finding), HPV test (all 
women with HPV test as follow-up to ASC-US, regardless of other tests), or colposcopy 
(with no HPV or Pap associated with the initial ASC-US Pap). Women who did not receive 
any follow-up procedure after the initial ASC-US Pap test through the NBCCEDP during 
the study period were classified as lost to follow-up. Pearson Chi-square tests were 
performed to test the null hypothesis of no association between follow-up groups and age 
groups and the null hypothesis of no association between follow-up groups and racial/ethnic 
groups. The percentage of women in each follow-up group was calculated separately for 
each age group and racial/ethnic group. To estimate confidence limits for the follow-up 
group percentages by age group, SUDAAN software [10] was used to fit a polytomous logit 
model for follow-up group with age group as the covariate, and the percentages and 
confidence limits were calculated using the predictive margins method [11]. The same 
approach was used for the follow-up group percentages by racial/ethnic group.
Results
Of the 45,049 ASC-US Pap test results examined in this analysis, 28,271 (62.8 %) were 
followed with an HPV test (Fig. 1), 3,883 (8.6 %) with a repeat Pap test, 6,592 (14.6 %) 
with a colposcopy (i.e., direct to colposcopy without an HPV test), and 6,303 (14.0 %) were 
lost to follow-up. Among the 11,951 women who had a positive HPV test result after an 
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ASC-US Pap test, 10,410 (87.1 %) had a colposcopy (Fig. 1). Of these women, 4,185 (40.2 
%) had normal results, 4,839 (46.5 %) were diagnosed with CIN 1, and 1,231 (11.8 %) were 
diagnosed with CIN 2, CIN 3, or cervical carcinoma in situ. Invasive cervical cancers were 
detected among 22 (0.2 %) women after an ASC-US Pap with a positive reflex HPV test.
The proportion of women followed with an HPV test increased with age up to 40–49 years 
(Table 1). Women aged <40 were followed more often with a colposcopy than older women. 
Women aged 18–20 years had the highest percentage of lost to follow-up (22 %; 95 % CI 
18.6–25.8), while those aged 21–29 years had the lowest percentage (6.1 %; 95 % CI 5.6–
6.7); the proportion of women lost to follow-up increased with age over 30 years.
By race/ethnicity, about 65 % of white, black, and API women were followed with an HPV 
test after an ASC-US Pap. Hispanic women (21.9 %; 95 % CI 21.2–22.7) and those of 
multiple races (18.8 %; 95 % CI 16.6–21.1) had the highest percent of colposcopy. API 
(13.0 %; 95 % CI 11.5–14.7) and AI/AN (12.6 %; 95 % CI 11.2–14.2) women had the 
highest proportion of repeat Pap tests as follow-up. AI/AN women had the highest 
proportion of being lost to follow-up than other racial/ethnic groups. Figure 2 shows the 
distribution of HPV positivity (among those tested for HPV, the percent that were positive) 
by age and race/ethnicity. Of those followed with an HPV test, women aged 18–20 and 21–
29 years had the highest proportions of HPV positivity (73.6 and 82.5 %, respectively). By 
race, AI/AN women had the highest proportion of HPV positivity (55.2 %).
Conclusion
Reflex HPV testing has been adopted as a cervical cancer screening strategy nationally by 
organizations and providers [12, 13]. During 2009–2011, nearly two-thirds of women in the 
NBCCEDP with an ASC-US Pap test result were managed with a reflex HPV test (62.8 %) 
and 87.1 % of women with HPV-positive results had additional diagnostic testing, in 
accordance with national guidelines. During our 3-year study period, HPV testing for 
follow-up of an ASC-US Pap test result was the preferred triage option according to 2006 
ASCCP guidelines; other methods remained acceptable [5].
These findings that providers serving the NBCCEDP women are following national 
guidelines for management of abnormal cytology are consistent with other studies. Benard et 
al. [14] found that providers were following women in the NBCCEDP with low-grade 
abnormalities according to national guidelines for the study period. Additionally, national 
provider surveys have found that providers serving women in the NBCCEDP had similar 
results on screening and management beliefs and practices compared to providers who do 
not serve women in the NBCCEDP [15].
Updated 2012 ASCCP management guidelines continued to emphasize the move toward 
reflex testing for follow-up of ASC-US results, followed by colposcopy for HPV-positive 
women; immediate colposcopy after an ASC-US finding is no longer acceptable. These 
changes were based on research demonstrating that reflex testing after ASC-US results 
identifies most CIN 3 lesions, yet refers many fewer women to colposcopy [16, 17]. 
Comparing the combined percentages of CIN 3 and invasive cancer among those women 
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who went immediately to colposcopy after the first ASC-US Pap test to results from those 
women who were triaged with an HPV test and referred to a colposcopy if HPV positive, we 
find very similar results (4.3 vs. 4.5 %, respectively; see Fig. 1), confirming that reflex HPV 
testing is effective at identifying abnormalities while lowering rates of colposcopy.
Our study documented differences in treatment patterns by race/ethnicity, which have been 
noted previously [14]. AI/AN women had the highest rates of HPV positivity in our study 
and also the highest rate of no follow-up (25 %). AI/AN women have persistent disparities 
in cervical cancer incidence and mortality, despite efforts resulting in some declines in 
cervical cancer among this population [18]. Rates of HPV positivity among AI/AN women 
have not previously been shown to differ substantially from other racial/ethnic groups [19]. 
Reasons for higher rates of no follow-up among AI/AN women are unclear, and more 
research is needed to determine whether these differences are related to data collection or 
less follow-up among these women. The high percentage (14 %) of women with no follow-
up in the study cohort overall is concerning; however, women in the NBCCEDP often have 
changes in income or insurance status, affecting their eligibility, and thus some women may 
have received subsequent screening and diagnostic services outside of the NBCCEDP.
Women younger than age 40 years were less often followed with a reflex HPV test in this 
study. Nearly one out of three women under the age of 40 in our study cohort with an ASC-
US Pap test result had an immediate colposcopy, raising concerns about potential 
overdiagnosis or overtreatment in this group. Women in this age group, especially younger 
than age 30, have a low risk of developing cervical cancer and may experience particular 
harms from treatment of abnormal lesions during the reproductive years [20–22]. This 
finding regarding more colposcopies as compared to repeat Pap tests for follow-up in the 
younger age group has been shown previously in the NBCCEDP [14, 23]. Women younger 
than age 40 are five times as likely to be enrolled in the NBCCEDP for diagnostic follow-up 
of an abnormal screening test performed elsewhere as women aged 40 and older (6.5 and 1.3 
%, respectively) (data not shown). Although we limited our cohort to women not previously 
screened within the NBCCEDP during the study period, some younger women may have 
been referred in from another screening (for instance, at a health fair) with abnormal results, 
which could contribute to higher rates of immediate colposcopy among younger women (if 
abnormal results had been reported elsewhere). Therefore, the younger women may 
represent a group at higher risk of HPV exposure and abnormal Pap results than those in the 
general population. Because many state programs direct outreach to women eligible for both 
breast and cervical cancer screening, the majority of the women screened in the NBCCEDP 
are over age 40.
Our study had some limitations. We lacked information on follow-up screenings conducted 
outside of the NBCCEDP or on other factors that may influence a provider's follow-up and 
management plan, for example previous abnormal tests outside of NBCCEDP or current 
pregnancy.
This is the first analysis describing follow-up results of women with ASC-US Pap test 
results in the NBCCEDP, focusing on HPV test use. This large collection of clinical data 
provides a window into the practices of thousands of providers across the USA, operating in 
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a multitude of clinical settings. Although our study took place during a period of changing 
guidelines, a majority of women with an ASC-US Pap test result were followed with the 
preferred method (62.8 % HPV test) according to guidelines and received recommended 
management if they were found to be HPV positive (87.1 % colposcopy performed). CDC 
frequently communicates information to state programs regarding changes in screening and 
management guidelines. The NBCCEDP has workgroups that meet regularly to promote 
education and training around evidence-based guidelines. This study demonstrates that 
providers in NBCCEDP largely appear to be practicing according to current guidelines for 
follow-up of ASC-US Pap tests.
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Management of women with atypical squamous cells of undetermined significance (ASC-
US) on cytology (n = 45,049). Note of women who had a repeat cytology within 15 months, 
26 (0.7 %) had unsatisfactory results and eight (0.2 %) had “other” results. Of HPV+ women 
who had a colposcopy, 133 (1.3 %) had “other” results. Of women who received a 
colposcopy without an HPV test, 205 (3.1 %) had “other” results
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Percent of HPV-positive test results after follow-up of ASC-US Pap test, NBCCEDP, 2009–
2011 (HPV positivity among those followed up with an HPV test)
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Table 1
Demographics and management of women with an ASC-US Pap test in the NBCCEDP, 2009–2011
Follow-up with HPV test Immediate colposcopy Repeat Pap No follow-up; lost to follow-up
p value*
n % (95 % CI) n % (95 % CI) n % (95 % CI) n % (95 % CI)
Age in years
 18–20 242 47.5 (43.2–51.9) 121 23.8 (20.3–27.7) 34 6.7 (4.8–9.2) 112 22.0 (18.6–25.8) <0.001
 21–29 4,310 53.5 (52.4–54.6) 2,956 36.7 (35.7–37.8) 294 3.7 (3.3–4.1) 494 6.1 (5.6–6.7)
 30–39 3,258 57.8 (56.5–59.1) 1,422 25.2 (24.1–26.4) 350 6.2 (5.6–6.9) 605 10.7 (10.0–11.6)
 40–49 10,790 67.6 (66.8–68.3) 1,211 7.6 (7.2–8.0) 1,473 9.2 (8.8–9.7) 2,496 15.6 (15.1–16.2)
 50–64 9,533 65.0 (64.2–65.8) 864 5.9 (5.5–6.3) 1,712 11.7 (11.2–12.2) 2,557 17.4 (16.8–18.1)
 65+ 138 64.2 (57.6–70.3) 18 8.4 (5.3–12.9) 20 9.3 (6.1–14.0) 39 18.1 (13.5–23.9)
Race/ethnicity
 White 13,998 65.6 (65.0–66.3) 2,625 12.3 (11.9–12.8) 1,914 9.0 (8.6–9.4) 2,795 13.1 (12.7–13.6) <0.001
 Black 3,925 64.6 (63.4–65.8) 699 11.5 (10.7–12.3) 480 7.9 (7.2–8.6) 971 16.0 (15.1–16.9)
 API 1,101 65.3 (63.0–67.5) 105 6.2 (5.2–7.5) 219 13.0 (11.5–14.7) 261 15.5 (13.8–17.3)
 AI/AN 1,065 56.4 (54.2–58.7) 113 6.0 (5.0–7.2) 238 12.6 (11.2–14.2) 471 25.0 (23.1–27.0)
 Multiracial/unknown 706 61.1 (58.3–63.9) 217 18.8 (16.6–21.1) 69 6.0 (4.7–7.5) 163 14.1 (12.2–16.2)
 Hispanic 7,476 57.9 (57.0–58.7) 2,833 21.9 (21.2–22.7) 963 7.5 (7.0–7.9) 1,642 12.7 (12.2–13.3)
*
p value from Pearson Chi-square test of the null hypothesis of no association between follow-up groups and demographic groups
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